SCHEMBL4265366

SCHEMBL4265366

O=C1COc2ccc(-c3nc(-c4cccnc4)cs3)cc2N1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.69
ALDH1A1 P00352 8/20 0.69
RAB9A P51151 5/20 0.69
NPC1 O15118 4/20 0.69
SMN1; SMN2 Q16637 4/20 0.69
MAPK1 P28482 3/20 0.69
MEN1 O00255 3/20 0.69
KMT2A Q03164 3/20 0.69
POLB P06746 2/20 0.65
HPGD P15428 1/20 0.62
CYP11B1 P15538 1/20 0.58
CYP11B2 P19099 1/20 0.58
LMNA P02545 3/20 0.58
TP53 P04637 1/20 0.58
CYP19A1 P11511 8/20 0.54
AXL P30530 1/20 0.54
PBRM1 Q86U86 1/20 0.54
MKNK1 Q9BUB5 1/20 0.54
MKNK2 Q9HBH9 1/20 0.54
HTT P42858 2/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4272682 0.89 MAPT (0.74) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL4267996 0.87 POLB (0.77) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL4267371 0.85 POLB (0.68) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL4271505 0.84 MAPT (0.74) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL4271523 0.84 MAPT (0.77) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL4262010 0.84 MAPT (0.74) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL4262035 0.84 ALDH1A1 (0.74) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL4272560 0.84 MAPT (0.74) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL4260402 0.84 MAPT (0.74) MAPTALDH1A1RAB9ANPC1SMN1; SMN2
SCHEMBL4260359 0.84 ALDH1A1 (0.64) MAPTALDH1A1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US claimed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS NR5A1, ESRRA, NR3C1 MAPT 3273/4885ALDH1A1 3483/4885RAB9A 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.